Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Oct 25;11(11):2580.
doi: 10.3390/nu11112580.

Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study

Giuseppa Castellino  1 , Dragana Nikolic  1 , Antonio Magán-Fernández  1   2 , Giuseppe Antonio Malfa  3 , Roberta Chianetta  1 , Angelo M Patti  1 , Antonella Amato  4 , Giuseppe Montalto  1 , Peter P Toth  5   6 , Maciej Banach  7 , Arrigo F G Cicero  8 , Manfredi Rizzo  1
Affiliations
Randomized Controlled Trial

Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study

Giuseppa Castellino et al. Nutrients. .

Abstract

The objective was to evaluate the effects of 6 months of supplementation with Altilix®, containing chlorogenic acid and its derivatives, and luteolin and its derivatives, on cardiovascular risk and hepatic markers in subjects with metabolic syndrome (MetS). A randomized, double-blind, placebo-controlled study was performed in 100 subjects with MetS with a follow-up period of 6 months; 50 subjects were randomized to Altilix® (26 men and 24 women, mean age 63 ± 8 years) and the other 50 to placebo (28 men and 22 women, mean age 63 ± 11 years). Anthropometric, cardiometabolic, and hepatic parameters were assessed at baseline and at the end of follow-up. Carotid intima-media thickness and endothelial function were assessed by doppler ultrasound and by flow-mediated dilation of the brachial artery, respectively. The presence and degree of non-alcoholic fatty liver disease (NAFLD) was assessed by the fatty liver index (FLI), and subjects were divided into three subgroups: (1) without NAFLD; (2) with borderline NAFLD; and (3) with NAFLD. After 6 months of Altilix® supplementation, we found a significant improvement vs. placebo in most of the evaluated parameters, including body weight (-2.40% (95% CI -3.79, -1.01); p < 0.001), waist circumference (-2.76% (95% CI -4.55, -0.96); p = 0.003), HbA1c (-0.95% (95% CI -1.22, -0.67); p < 0.001), plasma lipids, FLI (-21.83% (95% CI -27.39, -16.27); p < 0.001), hepatic transaminases, flow-mediated dilation (10.56% (95% CI 5.00, 16.12); p < 0.001), and carotid intima-media thickness (-39.48% (95% CI -47.98, -30.97); p < 0.001). Further, the improvement in cardiometabolic variables was independent of the degree of hepatic steatosis. Altilix® supplementation improved hepatic and cardio-metabolic parameters in MetS subjects. Altilix® supplementation was a beneficial approach in the management of hepatic and cardiometabolic alterations in MetS subjects.

Keywords: cardiovascular diseases; cynara; diabetes mellitus; dietary supplements; metabolic syndrome; non-alcoholic fatty liver disease; type 2.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of study.
Figure 2
Figure 2
Box plots of fatty liver index (FLI) percentage change at the end of the study in all subjects, according to the baseline presence and degree of NAFLD (n = 100).
See this image and copyright information in PMC

References

    1. Mikhailidis D.P., Elisaf M., Rizzo M., Berneis K., Griffin B., Zambon A., Athyros V., de Graaf J., Marz W., Parhofer K.G., et al. “European panel on low density lipoprotein (ldl) subclasses”: A statement on the pathophysiology, atherogenicity and clinical significance of ldl subclasses. Curr. Vasc. Pharmacol. 2011;9:533–571. doi: 10.2174/157016111796642661. - DOI - PubMed
    1. Perez-Martinez P., Mikhailidis D.P., Athyros V.G., Bullo M., Couture P., Covas M.I., de Koning L., Delgado-Lista J., Diaz-Lopez A., Drevon C.A., et al. Lifestyle recommendations for the prevention and management of metabolic syndrome: An international panel recommendation. Nutr. Rev. 2017;75:307–326. doi: 10.1093/nutrit/nux014. - DOI - PMC - PubMed
    1. Levene A.P., Goldin R.D. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology. 2012;61:141–152. doi: 10.1111/j.1365-2559.2011.04145.x. - DOI - PubMed
    1. Fazel Y., Koenig A.B., Sayiner M., Goodman Z.D., Younossi Z.M. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017–1025. doi: 10.1016/j.metabol.2016.01.012. - DOI - PubMed
    1. Dobson R., Burgess M.I., Sprung V.S., Irwin A., Hamer M., Jones J., Daousi C., Adams V., Kemp G.J., Shojaee-Moradie F., et al. Metabolically healthy and unhealthy obesity: Differential effects on myocardial function according to metabolic syndrome, rather than obesity. Int. J. Obes. 2016;40:153–161. doi: 10.1038/ijo.2015.151. - DOI - PubMed

Publication types